| Literature DB >> 26604860 |
Julia S Schwarz1, Hugo R de Jonge2, John N Forrest3.
Abstract
Organoids have tremendous therapeutic potential. They were recently defined as a collection of organ-specific cell types, which self-organize through cell-sorting, develop from stem cells, and perform an organ specific function. The ability to study organoid development and growth in culture and manipulate their genetic makeup makes them particularly suitable for studying development, disease, and drug efficacy. Organoids show great promise in personalized medicine. From a single patient biopsy, investigators can make hundreds of organoids with the genetic landscape of the patient of origin. This genetic similarity makes organoids an ideal system in which to test drug efficacy. While many investigators assume human organoids are the ultimate model system, we believe that the generation of epithelial organoids of comparative model organisms has great potential. Many key transport discoveries were made using marine organisms. In this paper, we describe how deriving organoids from the spiny dogfish shark, zebrafish, and killifish can contribute to the fields of comparative biology and disease modeling with future prospects for personalized medicine.Entities:
Keywords: Danio rerio; Fundulus heteroclitus; Squalus acanthias; cystic fibrosis; organoids
Mesh:
Year: 2015 PMID: 26604860 PMCID: PMC4654185
Source DB: PubMed Journal: Yale J Biol Med ISSN: 0044-0086
Figure 1Key events in the history of various organoid methodologies. From: Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125. Katharine Sutliff/Science. Reprinted with permission from Science.
Growth Factors and Culture Medium for Human Organoids.
|
|
|
|
| DMEM/F12 AdDMEM/F12 (Invitrogen) | DMEM/F12 | low concentration basic fibroblast growth factor (4 ng ml−1) |
| 1% N2 and 1% B27 (GIBCO) | penicillin and streptomycin | 50 μM Rho-associated protein kinase (ROCK) inhibitor49 (Calbiochem) |
| 1.25 mM N-Acetylcysteine (Sigma) | 10 mM HEPES | 100 N2 supplement (Invitrogen) |
| 10 nM gastrin (Sigma) | Glutamax N2, B27 (all from Invitrogen) | Glutamax (Invitrogen) |
| 50 ng/ml EGF (Peprotech) | 1 μM N-acetylcysteine (Sigma) | minimum essential media-nonessential amino acids (MEM-NEAA) |
| 10% RSPO1 conditioned media (homemade) | 50 ng ml−1 mouse epidermal growth factor (mEGF) | 1 μg ml−1 heparin50 (Sigma) |
| 100 ng/ml FGF10 (Peprotech) | 50% Wnt3a-conditioned medium (WCM) | 1:1 mixture of DMEM/F12 |
| 25 ng/ml HGF (Peprotech) | 10% noggin-conditioned medium (NCM) | 1:200 N2 supplement (Invitrogen) |
| 10 mM Nicotinamide (Sigma) | 20% Rspo1-conditioned medium | 1:100 B27 supplement without vitamin A (Invitrogen) |
| 5 uM A83.01 (Tocris) | 10 μM nicotinamide (Sigma) | 3.5 μl l−1 2-mercaptoethanol |
| 10 uM FSK (Tocris) | 10 nM gastrin (Sigma) | 1:4,000 insulin (Sigma) |
| Noggin (Peprotech) | 500 nM A83-01 (Tocris) | 1:100 Glutamax (Invitrogen) |
| 30% Wnt CM (homemade) | 10 μM SB202190 (Sigma) | 1:200 MEM-NEAA |
| 10 uM (Y27632, Sigma Aldrich) | Matrigel | B27 supplement with vitamin A (Invitrogen) |
| Matrigel | Matrigel |
Figure 2Procedure and Uses of Organoids from Comparative Model Organisms. Sacrifice of a dogfish shark provides a rectal gland. The gland is minced into SRG tubular cells, which are suspended in Matrigel. Organoids of the SRG are generated and passed continuously with high genetic stability. These organoids can be studied using the FIS assay. The CRISPR/Cas9 system can be used to put CFTR-/- or F508del-CFTR 508 into the organoids to examine if the SRG organoids will develop CF or if other amino acids in the shark channel could provide the function of the missing amino acids.
Figure 3Future Steps of Organoid Development from Comparative Model Organisms.